Anna V. Aksenova
Research Subjects
Anna V. Aksenova has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Irina Evgenievna Chazova
E.I. Chazov National Medical Research Center Of Cardiology
19 shared publications - Elena V. Oshchepkova
Chazov National Medical Research Center of Cardiology
10 shared publications - Aleksej A. Orlovsky
National Medical Research Center of Cardiology
4 shared publications - Ivan S. Serov
Cardiological dispensary
4 shared publications - Olga A. Belova
Cardiology Dispensary
4 shared publications - Svetlana A. Rachkova
Cardiological dispensary
4 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (8) , 472-477
Arterial hypertension and bronchial asthma: phenotype, cardiovascular complications, and independent predictors – an analysis of 57,396 patients from a hypertension registry
Background. The combination of arterial hypertension (AH) and bronchial asthma (BA) presents a complex clinical challenge that notably elevates cardiovascular risk. Real-world data are scarce regarding the phenotype and incidence of cardiovascular complications within this patient population. Aim. To investigate the prevalence of cardiovascular risk factors and comorbidities in patients with AH, taking into account the presence of BA, as recorded in the national hypertension registry. Materials and methods. Retrospective analysis of a hypertension registry: 56,784 AH patients without BA and 612 with AH+BA. Demographic and anthropometric parameters and comorbidity prevalence were compared. Odds ratios (OR) were adjusted for sex and age. Results. BA prevalence was 1.1%. The AH+BA phenotype was characterized by female predominance (71.4% vs 59.4%; p0.001), older age (65.0 years vs 62.7 years; p0.001), higher BMI (29.4 kg/m2 vs 28.5 kg/m2; p=0.002), and abdominal obesity (53.7% vs 39.0%; p=0.003). BA was associated with higher rates of coronary artery disease – CAD (56.2% vs 41.2%), chronic heart failure – CHF (68.8% vs 48.6%), and atrial fibrillation – AF (10.1% vs 4.3%; all p0.001). After adjustment, BA remained an independent predictor of CAD (OR 2.02, 95% confidence interval – CI 1.71–2.40), CHF (OR 2.47, 95% CI 2.07–2.96), and AF (OR 2.49, 95% CI 1.88–3.23). No association with stroke was found. Conclusion. The comorbidity of BA and AH is associated with a distinct phenotype (older woman with abdominal obesity). BA is an independent predictor of CAD, CHF, and AF, mandating active cardiovascular screening.
- 18 August 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (8) , 472-477
Open AccessArterial hypertension and bronchial asthma: phenotype, cardiovascular complications, and independent predictors – an analysis of 57,396 patients from a hypertension registry
Background. The combination of arterial hypertension (AH) and bronchial asthma (BA) presents a complex clinical challenge that notably elevates cardiovascular risk. Real-world data are scarce regarding the phenotype and incidence of cardiovascular complications within this patient population. Aim. To investigate the prevalence of cardiovascular risk factors and comorbidities in patients with AH, taking into account the presence of BA, as recorded in the national hypertension registry. Materials and methods. Retrospective analysis of a hypertension registry: 56,784 AH patients without BA and 612 with AH+BA. Demographic and anthropometric parameters and comorbidity prevalence were compared. Odds ratios (OR) were adjusted for sex and age. Results. BA prevalence was 1.1%. The AH+BA phenotype was characterized by female predominance (71.4% vs 59.4%; p0.001), older age (65.0 years vs 62.7 years; p0.001), higher BMI (29.4 kg/m2 vs 28.5 kg/m2; p=0.002), and abdominal obesity (53.7% vs 39.0%; p=0.003). BA was associated with higher rates of coronary artery disease – CAD (56.2% vs 41.2%), chronic heart failure – CHF (68.8% vs 48.6%), and atrial fibrillation – AF (10.1% vs 4.3%; all p0.001). After adjustment, BA remained an independent predictor of CAD (OR 2.02, 95% confidence interval – CI 1.71–2.40), CHF (OR 2.47, 95% CI 2.07–2.96), and AF (OR 2.49, 95% CI 1.88–3.23). No association with stroke was found. Conclusion. The comorbidity of BA and AH is associated with a distinct phenotype (older woman with abdominal obesity). BA is an independent predictor of CAD, CHF, and AF, mandating active cardiovascular screening.
- 1 April 2026
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 23 (1)
Clinical Profile and Antihypertensive Treatment Patterns in Patients with Comorbid Hypertension and Type 2 Diabetes Mellitus: Insights from the National Hypertension Registry
Relevance. The high prevalence of diabetes mellitus among patients with hypertension and the increased risk of cardiovascular complications necessitate a more detailed study of the characteristics of this patient group in order to optimize their management approach. Objective. To identify clinical features of comorbid patients with hypertension and diabetes mellitus, as well as to assess their treatment. Materials and methods. 57396 ambulatory patients from the national registry of hypertension were included in this study. They were divided into 2 groups based on the presence of absence of diabetes mellitus. The assessment of social and anthropometric factors, medical history, modifiable cardio-vascular risk factors was conducted. Statistical analysis was done using R 4.3.3 environment (R foundation for Statistical Computing, Vienna, Austria). Results. Type 2 diabetes mellitus (T2DM) was detected in 15.3% of patients with hypertension (HTN). The group of patients with HTN and type 2 diabetes mellitus was predominantly represented by women (66.6%), who most often had risk factors such as obesity (55.4%) and low physical activity (40.3%). Compared to hypertensive patients without T2DM, those with hypertension and T2DM had significantly higher rates of chronic heart failure (64.4% vs 46.0%), coronary artery disease (54.9% vs 39.0%), chronic kidney disease (35.8% vs 28.3%), and prior cerebrovascular events (7.0% vs 4.1%). Patients with hypertension combined with T2DM demonstrated greater treatment resistance, with more frequent prescriptions of angiotensin receptor blockers (24.7% vs 16.7%), beta-blockers (59.5% vs 51.5%), and calcium channel blockers (22.3% vs 15.1%). Conclusions. The identified changes reflect an additional negative impact of type 2 diabetes on the course of hypertension and the development of cardiovascular complications. Due to the high burden of cardiac and non-cardiac pathologies in this patient group, a more aggressive and multicomponent approach to therapy is required. The obtained results emphasize the need for the development of comprehensive programs for prevention, early diagnosis, and an individualized approach to prescribing therapy. The combination of hypertension and type 2 diabetes in the Russian federation necessitates an interdisciplinary approach with an emphasis on controlling metabolic parameters and the early prevention of complications.
- 1 April 2026
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 23 (1)
Clinical Profile and Antihypertensive Treatment Patterns in Patients with Comorbid Hypertension and Type 2 Diabetes Mellitus: Insights from the National Hypertension Registry
Relevance. The high prevalence of diabetes mellitus among patients with hypertension and the increased risk of cardiovascular complications necessitate a more detailed study of the characteristics of this patient group in order to optimize their management approach. Objective. To identify clinical features of comorbid patients with hypertension and diabetes mellitus, as well as to assess their treatment. Materials and methods. 57396 ambulatory patients from the national registry of hypertension were included in this study. They were divided into 2 groups based on the presence of absence of diabetes mellitus. The assessment of social and anthropometric factors, medical history, modifiable cardio-vascular risk factors was conducted. Statistical analysis was done using R 4.3.3 environment (R foundation for Statistical Computing, Vienna, Austria). Results. Type 2 diabetes mellitus (T2DM) was detected in 15.3% of patients with hypertension (HTN). The group of patients with HTN and type 2 diabetes mellitus was predominantly represented by women (66.6%), who most often had risk factors such as obesity (55.4%) and low physical activity (40.3%). Compared to hypertensive patients without T2DM, those with hypertension and T2DM had significantly higher rates of chronic heart failure (64.4% vs 46.0%), coronary artery disease (54.9% vs 39.0%), chronic kidney disease (35.8% vs 28.3%), and prior cerebrovascular events (7.0% vs 4.1%). Patients with hypertension combined with T2DM demonstrated greater treatment resistance, with more frequent prescriptions of angiotensin receptor blockers (24.7% vs 16.7%), beta-blockers (59.5% vs 51.5%), and calcium channel blockers (22.3% vs 15.1%). Conclusions. The identified changes reflect an additional negative impact of type 2 diabetes on the course of hypertension and the development of cardiovascular complications. Due to the high burden of cardiac and non-cardiac pathologies in this patient group, a more aggressive and multicomponent approach to therapy is required. The obtained results emphasize the need for the development of comprehensive programs for prevention, early diagnosis, and an individualized approach to prescribing therapy. The combination of hypertension and type 2 diabetes in the Russian federation necessitates an interdisciplinary approach with an emphasis on controlling metabolic parameters and the early prevention of complications.
- Open Access
- 20 December 2025
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 22 (4) , 59-68
Clinical portrait and distinctive features of antihypertensive therapy in comorbid patients with Hypertension and gout according to the national hypertension registry
Relevance. The increasing prevalence of gout among patients with hypertension and other cardio-vascular diseases, as well as harmful influence on cardio- vascular risk warrant the need for more scrupulous examination and multidisciplinary approach to hypertensive patients with gout. Aim. To identify clinical features of comorbid patients with hypertension and gout, as well as to assess their treatment. Materials and methods. 57396 ambulatory patients from the national registry of hypertension were included in this study. They were divided into 2 groups based on the presence of gout. The assessment of social and anthropometric factors, medical history, modifiable cardio-vascular risk factors was conducted. Statistical analysis was done using R 4.3.3 environment (R Foundation for Statistical Computing, Vienna, Austria). Results. 0,6% of hypertensive patients had gout. Patients with gout more frequently had chronic heart failure (63,9%), ischemic heart disease (52,5%), chronic kidney disease (39,8%), transient ischemic attack (3,1%). The majority of patients were men (65,1%) with such risk factors as obesity (52,5%), smoking (71,8%), alcohol intake (47,3%), sedentary lifestyle (37,8%) and poor diet (48,9%). They were also more frequently diagnosed with diabetes mellitus – 26,2% and liver cirrhosis (1,5%). The specific treatment features of this group of patients include more frequent therapy with angiotensin receptor blockers (30,9%) and loop diuretics – 13,6%. Conclusion. Despite relatively low prevalence of gout in general population of patients with hypertension, this comorbid group of patients has high cardio- vascular risk and is characterised by exceptionally high presence of additional cardiac and non-cardiac pathologies. Distinctive features of treatment reflect the necessity of adaptive approach in order to meet the additional needs of these patients, including treatment of chronic heart failure and chronic kidney disease. Results of this study emphasise the necessity to implement a multidisciplinary approach in management of these patients, involving the aggressive modification of any risk factors and selection of a rational pharmacological treatment, based on concomitant pathology.
- 20 December 2025
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 22 (4) , 59-68
Open AccessClinical portrait and distinctive features of antihypertensive therapy in comorbid patients with Hypertension and gout according to the national hypertension registry
Relevance. The increasing prevalence of gout among patients with hypertension and other cardio-vascular diseases, as well as harmful influence on cardio- vascular risk warrant the need for more scrupulous examination and multidisciplinary approach to hypertensive patients with gout. Aim. To identify clinical features of comorbid patients with hypertension and gout, as well as to assess their treatment. Materials and methods. 57396 ambulatory patients from the national registry of hypertension were included in this study. They were divided into 2 groups based on the presence of gout. The assessment of social and anthropometric factors, medical history, modifiable cardio-vascular risk factors was conducted. Statistical analysis was done using R 4.3.3 environment (R Foundation for Statistical Computing, Vienna, Austria). Results. 0,6% of hypertensive patients had gout. Patients with gout more frequently had chronic heart failure (63,9%), ischemic heart disease (52,5%), chronic kidney disease (39,8%), transient ischemic attack (3,1%). The majority of patients were men (65,1%) with such risk factors as obesity (52,5%), smoking (71,8%), alcohol intake (47,3%), sedentary lifestyle (37,8%) and poor diet (48,9%). They were also more frequently diagnosed with diabetes mellitus – 26,2% and liver cirrhosis (1,5%). The specific treatment features of this group of patients include more frequent therapy with angiotensin receptor blockers (30,9%) and loop diuretics – 13,6%. Conclusion. Despite relatively low prevalence of gout in general population of patients with hypertension, this comorbid group of patients has high cardio- vascular risk and is characterised by exceptionally high presence of additional cardiac and non-cardiac pathologies. Distinctive features of treatment reflect the necessity of adaptive approach in order to meet the additional needs of these patients, including treatment of chronic heart failure and chronic kidney disease. Results of this study emphasise the necessity to implement a multidisciplinary approach in management of these patients, involving the aggressive modification of any risk factors and selection of a rational pharmacological treatment, based on concomitant pathology.
- Open Access
- 29 October 2025
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 22 (3) , 5-18
Medical Society of Hypertension. Use of beta-blockers in patients with hypertension
This Russian Medical Society for Arterial Hypertension expert consensus describes the beta-blockers's role in treatment strategy of the arterial hypertension combined with cardiovascular diseases and other comorbidities, which may be more frequent in hypertensive patients than in patients with normal blood pressure level.
- 29 October 2025
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 22 (3) , 5-18
Open AccessMedical Society of Hypertension. Use of beta-blockers in patients with hypertension
This Russian Medical Society for Arterial Hypertension expert consensus describes the beta-blockers's role in treatment strategy of the arterial hypertension combined with cardiovascular diseases and other comorbidities, which may be more frequent in hypertensive patients than in patients with normal blood pressure level.
- Open Access
- 31 July 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (7) , 538-544
Clinical portrait and features of antihypertensive therapy in comorbid patients with arterial hypertension and chronic obstructive pulmonary disease according to the national hypertension registry
Background. Cardiovascular diseases (CVD) and chronic obstructive pulmonary disease (COPD) are the two leading causes of death in the world. Studies show a close mutually aggravating relationship between arterial hypertension (AH) and COPD. Antihypertensive therapy in patients with AH and COPD has a number of features, aiming to reduce the risk of developing cardiovascular complications and mortality from CVD without worsening lung function. Aim. To analyze the data of patients with AH and COPD included in the national registry to determine the burden of CVD risk factors, concomitant cardiovascular, cerebrovascular diseases and chronic kidney disease, obesity, diabetes mellitus, gout and characteristics of antihypertensive therapy. Materials and methods. A comparative analysis of patients of the hypertension registry (conducted in outpatient clinics) was performed depending on the presence (n=3323) or absence (n=54073) of chronic obstructive pulmonary disease. Statistical analysis of the obtained data were performed using the R 4.3.3 statistical computing environment (R Foundation for Statistical Computing, Vienna, Austria). Results. The prevalence of COPD in patients with hypertension was 5.8% (3323 cases). The presence of COPD in patients with hypertension, regardless of gender and age, was statistically significantly associated with higher odds of having coronary artery disease [odds ratio (OR) 2.21, 95% confidence interval (CI) 2.06–2.38; p0.001], a history of myocardial infarction (OR 1.73, 95% CI 1.59–1.87; p0.001), chronic heart failure (OR 1.95, 95% CI 1.82–2.1; p0.001), a history of acute cerebrovascular accident (OR 1.25, 95% CI 1.07–1.46; p=0.004), transient ischemic attack (OR 2.9, 95% CI 2.31–3.59; p0.001), atrial fibrillation (OR 1.68, 95% CI 1.45–1.93; p0.001). Patients with hypertension and COPD more often received drugs from the group of angiotensin-II receptor antagonists than patients with hypertension without COPD (22.7% vs 17.7%). The prescription of drugs from the group of beta-blockers in patients with hypertension and COPD was lower by 4%. Cardiovascular risk factors, comorbidities such as diabetes mellitus, gout, obstructive sleep apnea in patients with hypertension and COPD are more common. Conclusion. Patients with COPD and hypertension have a higher incidence of risk factors, CVD and comorbid pathologies. They require closer attention during examination and during the selection of antihypertensive therapy. In patients with hypertension and COPD, angiotensin-converting-enzyme inhibitors and beta-blockers are prescribed less frequently than in patients with hypertension without COPD due to possible side effects and contraindications.
- 31 July 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (7) , 538-544
Open AccessClinical portrait and features of antihypertensive therapy in comorbid patients with arterial hypertension and chronic obstructive pulmonary disease according to the national hypertension registry
Background. Cardiovascular diseases (CVD) and chronic obstructive pulmonary disease (COPD) are the two leading causes of death in the world. Studies show a close mutually aggravating relationship between arterial hypertension (AH) and COPD. Antihypertensive therapy in patients with AH and COPD has a number of features, aiming to reduce the risk of developing cardiovascular complications and mortality from CVD without worsening lung function. Aim. To analyze the data of patients with AH and COPD included in the national registry to determine the burden of CVD risk factors, concomitant cardiovascular, cerebrovascular diseases and chronic kidney disease, obesity, diabetes mellitus, gout and characteristics of antihypertensive therapy. Materials and methods. A comparative analysis of patients of the hypertension registry (conducted in outpatient clinics) was performed depending on the presence (n=3323) or absence (n=54073) of chronic obstructive pulmonary disease. Statistical analysis of the obtained data were performed using the R 4.3.3 statistical computing environment (R Foundation for Statistical Computing, Vienna, Austria). Results. The prevalence of COPD in patients with hypertension was 5.8% (3323 cases). The presence of COPD in patients with hypertension, regardless of gender and age, was statistically significantly associated with higher odds of having coronary artery disease [odds ratio (OR) 2.21, 95% confidence interval (CI) 2.06–2.38; p0.001], a history of myocardial infarction (OR 1.73, 95% CI 1.59–1.87; p0.001), chronic heart failure (OR 1.95, 95% CI 1.82–2.1; p0.001), a history of acute cerebrovascular accident (OR 1.25, 95% CI 1.07–1.46; p=0.004), transient ischemic attack (OR 2.9, 95% CI 2.31–3.59; p0.001), atrial fibrillation (OR 1.68, 95% CI 1.45–1.93; p0.001). Patients with hypertension and COPD more often received drugs from the group of angiotensin-II receptor antagonists than patients with hypertension without COPD (22.7% vs 17.7%). The prescription of drugs from the group of beta-blockers in patients with hypertension and COPD was lower by 4%. Cardiovascular risk factors, comorbidities such as diabetes mellitus, gout, obstructive sleep apnea in patients with hypertension and COPD are more common. Conclusion. Patients with COPD and hypertension have a higher incidence of risk factors, CVD and comorbid pathologies. They require closer attention during examination and during the selection of antihypertensive therapy. In patients with hypertension and COPD, angiotensin-converting-enzyme inhibitors and beta-blockers are prescribed less frequently than in patients with hypertension without COPD due to possible side effects and contraindications.
- Open Access
- 25 December 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (4) , 5-110
Clinical guidelines of the Russian Medical Society on arterial Hypertension (RSH) and the Eurasian association of Cardiologists (EaC) for the diagnosis and treatment of arterial hypertension (2024)
The сlinical guidelines present the main approaches to the management of patients with arterial hypertension (aH) using the principles of evidence-based medicine. The guidelines include sections containing expanded and updated information on the main aspects of diagnosis, treatment, prevention methods and follow-up patients with hypertension, taking into account the phenotypes of disease and various clinical situations, as well as secondary forms of hypertension of various origins.
- 25 December 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (4) , 5-110
Open AccessClinical guidelines of the Russian Medical Society on arterial Hypertension (RSH) and the Eurasian association of Cardiologists (EaC) for the diagnosis and treatment of arterial hypertension (2024)
The сlinical guidelines present the main approaches to the management of patients with arterial hypertension (aH) using the principles of evidence-based medicine. The guidelines include sections containing expanded and updated information on the main aspects of diagnosis, treatment, prevention methods and follow-up patients with hypertension, taking into account the phenotypes of disease and various clinical situations, as well as secondary forms of hypertension of various origins.
- Open Access
- 10 October 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (9) , 860-871
Antihypertensive therapy in patients with arterial hypertension and concomitant diseases in real clinical practice (according to the National Registry of Arterial Hypertension, 2019–2022)
Background. Arterial hypertension (AH) remains the leading risk factor associated with cardiovascular diseases (CVDs), cerebrovascular disease and chronic kidney disease. About 70% of patients with AH who are on monotherapy cannot achieve blood pressure (BP) targets, and therefore all quidelines for the management of AH have recently recommended prescribing combination therapy (PCT). In real clinical practice (RCP), there remains significant uncertainty in the effectiveness and rationality of therapy, despite the wide availability of antihypertensive drugs (AHD) and the presence of recommendations for a stepwise approach to prescribing combinations of specific groups of AHD in different clinical situations. Aim. Analyze the real ongoing antihypertensive therapy, including the PCT; international nonproprietary names of drugs and their dosages in RCP; compliance of therapy with clinical recommendations; changing trends in the PCT. Materials and methods. An analysis was carried out of the data from the register of AH, the compliance of treatment in different clinical groups of patients and the achievement of BP and low-density lipoprotein cholesterol targets in the sample of 2019–2022 (n=5012). The prescription of AHD and achievement of targets values were assessed in accordance with current clinical guidelines for the management of AH and hypercholesterolemia. Data from 2010 (n=7782) and 2020 (n=3061) were analyzed to assess the dynamics of prescription of monotherapy and PCT. Results. The greatest increase in the number of AHD was observed in patients with hypertension in combination with coronary heart disease, heart failure, and atrial fibrillation. In a small group of patients with hypertension without other CVDs, the recommended combinations of AHD were not prescribed; preference was given to angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and β-adrenoblocker (β-AB). PCT mainly differed from the recommended combinations by the wider use of drugs from the β-AB group. The PCT of recommended drugs was highest in patients with hypertension and coronary artery disease – more than 90%, hypertension and heart failure in 56.2%, hypertension and atrial fibrillation – 33.3%, hypertension and chronic kidney desease – 19.6%. Achievement of BP and low-density lipoprotein cholesterol targets was insufficient in all analyzed groups. Among the international nonproprietary names of drugs, the most frequently prescribed are the following: bisoprolol, metoprolol, lisinopril, perindopril, losartan, spironolactone, amlodipine, torasemide, indapamide, hypochlorothiazide, moxonidine. The prescribed daily dosages were closer to the initial recommended ones. By 2020, the prescription of PCT with β-AB and a more uniform prescription of various combinations will come to the fore, while PCT in 2010 is characterized by the presence of one or two leaders combinations. Conclusion. The described features of prescribing AHD partially reproduce clinical recommendations for the management of AH. Differences in therapy provided in RCP may be associated with an attempt to intensify the treatment of hypertension in patients with other concomitant CVDs. At the same time, analysis of combinations and dosages of prescribed drugs suggests the presence of wide opportunities for further escalation of therapy. The presented data can provide insight into current patterns of antihypertensive therapy prescription in patients in RCP and lay the foundation for optimizing therapy in different categories hypertensive patients.
- 10 October 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (9) , 860-871
Open AccessAntihypertensive therapy in patients with arterial hypertension and concomitant diseases in real clinical practice (according to the National Registry of Arterial Hypertension, 2019–2022)
Background. Arterial hypertension (AH) remains the leading risk factor associated with cardiovascular diseases (CVDs), cerebrovascular disease and chronic kidney disease. About 70% of patients with AH who are on monotherapy cannot achieve blood pressure (BP) targets, and therefore all quidelines for the management of AH have recently recommended prescribing combination therapy (PCT). In real clinical practice (RCP), there remains significant uncertainty in the effectiveness and rationality of therapy, despite the wide availability of antihypertensive drugs (AHD) and the presence of recommendations for a stepwise approach to prescribing combinations of specific groups of AHD in different clinical situations. Aim. Analyze the real ongoing antihypertensive therapy, including the PCT; international nonproprietary names of drugs and their dosages in RCP; compliance of therapy with clinical recommendations; changing trends in the PCT. Materials and methods. An analysis was carried out of the data from the register of AH, the compliance of treatment in different clinical groups of patients and the achievement of BP and low-density lipoprotein cholesterol targets in the sample of 2019–2022 (n=5012). The prescription of AHD and achievement of targets values were assessed in accordance with current clinical guidelines for the management of AH and hypercholesterolemia. Data from 2010 (n=7782) and 2020 (n=3061) were analyzed to assess the dynamics of prescription of monotherapy and PCT. Results. The greatest increase in the number of AHD was observed in patients with hypertension in combination with coronary heart disease, heart failure, and atrial fibrillation. In a small group of patients with hypertension without other CVDs, the recommended combinations of AHD were not prescribed; preference was given to angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and β-adrenoblocker (β-AB). PCT mainly differed from the recommended combinations by the wider use of drugs from the β-AB group. The PCT of recommended drugs was highest in patients with hypertension and coronary artery disease – more than 90%, hypertension and heart failure in 56.2%, hypertension and atrial fibrillation – 33.3%, hypertension and chronic kidney desease – 19.6%. Achievement of BP and low-density lipoprotein cholesterol targets was insufficient in all analyzed groups. Among the international nonproprietary names of drugs, the most frequently prescribed are the following: bisoprolol, metoprolol, lisinopril, perindopril, losartan, spironolactone, amlodipine, torasemide, indapamide, hypochlorothiazide, moxonidine. The prescribed daily dosages were closer to the initial recommended ones. By 2020, the prescription of PCT with β-AB and a more uniform prescription of various combinations will come to the fore, while PCT in 2010 is characterized by the presence of one or two leaders combinations. Conclusion. The described features of prescribing AHD partially reproduce clinical recommendations for the management of AH. Differences in therapy provided in RCP may be associated with an attempt to intensify the treatment of hypertension in patients with other concomitant CVDs. At the same time, analysis of combinations and dosages of prescribed drugs suggests the presence of wide opportunities for further escalation of therapy. The presented data can provide insight into current patterns of antihypertensive therapy prescription in patients in RCP and lay the foundation for optimizing therapy in different categories hypertensive patients.
- Open Access
- 1 October 2024
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 3,p. 6-27
Eurasian Association of Cardiology (EAC)/ Russian society of somnologists (RSS) guidelines for the diagnosis and treatment of obstructive sleep apnea in patients with cardiovascular diseases (2024)
The aim of this guideline is to assist physicians in the management of patients with cardiovascular pathology and obstructive sleep-disordered breathing. The article consists data on diagnostic tactics for patients with possible sleep-breathing disorders, describes the basic principles of obstructive sleep apnea treatment, and substantiates the clinical significance of obstructive sleep apnea therapy initiating in the management of patients with cardiovascular diseases.
- 1 October 2024
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 3,p. 6-27
Open AccessEurasian Association of Cardiology (EAC)/ Russian society of somnologists (RSS) guidelines for the diagnosis and treatment of obstructive sleep apnea in patients with cardiovascular diseases (2024)
The aim of this guideline is to assist physicians in the management of patients with cardiovascular pathology and obstructive sleep-disordered breathing. The article consists data on diagnostic tactics for patients with possible sleep-breathing disorders, describes the basic principles of obstructive sleep apnea treatment, and substantiates the clinical significance of obstructive sleep apnea therapy initiating in the management of patients with cardiovascular diseases.
- Open Access
- 25 June 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (2) , 19-26
Controlled and uncontrolled arterial hypertension: comparison of clinical and demographic characteristics in patients (according to the National Registry of Hypertension, 2019-2022)
Aim: to analyze the features of antihypertensive therapy in a sample of patients with arterial hypertension observed in primary healthcare (2019-2022), to identify the features of therapy in patients with uncontrolled and controlled hypertension. Materials and methods. An analysis was made of antihypertensive therapy in 4543 patients, the frequency of prescription of various combinations ofantihypertensive drugs. For statistical data processing, the SPSS statistical software package was used. Drug combinations prescribed in less than 2% of cases were excluded from the graphical presentation. Results. The majority of patients with hypertension were prescribed combined AHT (2, 3 and 4-component therapy represented in 28.3 %, 33 %, 24.8 %, respectively). More than 90 % of patients receive drugs that block the RAAS system, more than 85 % – BB. Every third patient received a CCB, diuretic therapy most often prescribed mineralocorticoid receptor antagonists (39.8 %), loop diuretics (20 %). Thiazide-like diuretics are prescribed 1.8 times more often than thiazide ones (18.6 % and 10.1 %). In the structure of monotherapy in patients with hypertension, the leading prescriptions are BBs, ACEIs and ARBs (43.3 %; 31.4 %; 15.1 %) with a high incidence of coronary heart disease and heart failure. Combinations of BB, ACEI and ARB form the most frequently prescribed double combinations (BB+ACEI – 48.3 %; ARB and BB – 22.8 %). Almost all of the most commonly prescribed 4-antihypertensive combinations contained MRA. Among patients with controlled and uncontrolled hypertension, the frequency of prescription of different classes of antihypertensive drugs as monotherapy did not differ. Features of combination therapy in patients with uncontrolled hypertension included more frequent prescription of BB+ARB (25.6 % vs. 20.8 %), BB+ARB+TlD (15.7 % vs. 10.3 %), BB+ARB+CCB (11.1% vs. 6.3 %), ARB+CCBd+TlD (2.9 % vs. 1 %), BB+BRA+CCBd+TlD (15.3 % vs. 8.1 %), BB+ ACEI+CCBd+TlD (7.1 % vs. 2 %), BB+ACEI+CCBd+TlD+AB (5.3 % vs. 0 %), BB+ARB+CCBd+TlD+AB (5.3 % vs. 0 %). Patients with controlled hypertension were more often prescribed BB+ACEI (53.5 % vs. 41.3 %), BB+ACEI+MRA (22.8 % vs. 13.5 %), BB+ACEI+LD (3.6 % vs. 1.4 %), BB+ACEI+LD+MRA (27.1 % vs. 14.1 %), BB+ACEI+CCBd+MRA (19.6 % vs. 5.8 %), BB+ACEI+TD+MRA+LD (2.5 times, (23.8 % vs. 9.6 %)), BB+ACEI+CCBd+MRA+TD (5 times, (14.9 % vs. 2.9 %). Сonclusions. Further escalation of the use of combination therapy is necessary given the high rate of failure to achieve target values.
- 25 June 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (2) , 19-26
Open AccessControlled and uncontrolled arterial hypertension: comparison of clinical and demographic characteristics in patients (according to the National Registry of Hypertension, 2019-2022)
Aim: to analyze the features of antihypertensive therapy in a sample of patients with arterial hypertension observed in primary healthcare (2019-2022), to identify the features of therapy in patients with uncontrolled and controlled hypertension. Materials and methods. An analysis was made of antihypertensive therapy in 4543 patients, the frequency of prescription of various combinations ofantihypertensive drugs. For statistical data processing, the SPSS statistical software package was used. Drug combinations prescribed in less than 2% of cases were excluded from the graphical presentation. Results. The majority of patients with hypertension were prescribed combined AHT (2, 3 and 4-component therapy represented in 28.3 %, 33 %, 24.8 %, respectively). More than 90 % of patients receive drugs that block the RAAS system, more than 85 % – BB. Every third patient received a CCB, diuretic therapy most often prescribed mineralocorticoid receptor antagonists (39.8 %), loop diuretics (20 %). Thiazide-like diuretics are prescribed 1.8 times more often than thiazide ones (18.6 % and 10.1 %). In the structure of monotherapy in patients with hypertension, the leading prescriptions are BBs, ACEIs and ARBs (43.3 %; 31.4 %; 15.1 %) with a high incidence of coronary heart disease and heart failure. Combinations of BB, ACEI and ARB form the most frequently prescribed double combinations (BB+ACEI – 48.3 %; ARB and BB – 22.8 %). Almost all of the most commonly prescribed 4-antihypertensive combinations contained MRA. Among patients with controlled and uncontrolled hypertension, the frequency of prescription of different classes of antihypertensive drugs as monotherapy did not differ. Features of combination therapy in patients with uncontrolled hypertension included more frequent prescription of BB+ARB (25.6 % vs. 20.8 %), BB+ARB+TlD (15.7 % vs. 10.3 %), BB+ARB+CCB (11.1% vs. 6.3 %), ARB+CCBd+TlD (2.9 % vs. 1 %), BB+BRA+CCBd+TlD (15.3 % vs. 8.1 %), BB+ ACEI+CCBd+TlD (7.1 % vs. 2 %), BB+ACEI+CCBd+TlD+AB (5.3 % vs. 0 %), BB+ARB+CCBd+TlD+AB (5.3 % vs. 0 %). Patients with controlled hypertension were more often prescribed BB+ACEI (53.5 % vs. 41.3 %), BB+ACEI+MRA (22.8 % vs. 13.5 %), BB+ACEI+LD (3.6 % vs. 1.4 %), BB+ACEI+LD+MRA (27.1 % vs. 14.1 %), BB+ACEI+CCBd+MRA (19.6 % vs. 5.8 %), BB+ACEI+TD+MRA+LD (2.5 times, (23.8 % vs. 9.6 %)), BB+ACEI+CCBd+MRA+TD (5 times, (14.9 % vs. 2.9 %). Сonclusions. Further escalation of the use of combination therapy is necessary given the high rate of failure to achieve target values.
- Open Access
- 25 March 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (1) , 5-13
Russian medical society expert consensus on arterial hypertension: use of fixed combinations in the treatment of patients with arterial hypertension
Despite the large arsenal of antihypertensive agents, BP control, both in Europe and in Russia, remains at a low level, more than 50% patients do not reach the goal BP levels. At the same time, data from the results of RCTs demonstrate that the achievement of goal BP values is possible in most patients, no more than 5-10% of patients have resistance to antihypertensive therapy. Sufficient evidence has been accumulated that low adherence to treatment remains afundamental contributing factor to insufficient BP control. There is evidence that adherence to treatment closely correlates with the complex dosing regimen of the drugs and the number of tablets taken. Low adherence has been shown to be associated with an increased risk of cardiovascular complications. Furthermore, evidence suggests that medical inertia contributes to treatment failure in patients remaining on monotherapy or receiving inadequate suboptimal therapy. The use of combination therapy, including the use of fixed combinations in most patients, can help to solve both problems. This consensus focuses on various issues related to the prescription of combination therapy in the form of fixed combinations and polypill.
- 25 March 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (1) , 5-13
Open AccessRussian medical society expert consensus on arterial hypertension: use of fixed combinations in the treatment of patients with arterial hypertension
Despite the large arsenal of antihypertensive agents, BP control, both in Europe and in Russia, remains at a low level, more than 50% patients do not reach the goal BP levels. At the same time, data from the results of RCTs demonstrate that the achievement of goal BP values is possible in most patients, no more than 5-10% of patients have resistance to antihypertensive therapy. Sufficient evidence has been accumulated that low adherence to treatment remains afundamental contributing factor to insufficient BP control. There is evidence that adherence to treatment closely correlates with the complex dosing regimen of the drugs and the number of tablets taken. Low adherence has been shown to be associated with an increased risk of cardiovascular complications. Furthermore, evidence suggests that medical inertia contributes to treatment failure in patients remaining on monotherapy or receiving inadequate suboptimal therapy. The use of combination therapy, including the use of fixed combinations in most patients, can help to solve both problems. This consensus focuses on various issues related to the prescription of combination therapy in the form of fixed combinations and polypill.